129$/KG
109$/KG
Product Detailed Description
liposomal Curcumin 70% is a premium-grade dietary supplement ingredient delivering curcumin in an advanced liposomal delivery system. Curcumin (diferuloylmethane or curcumin I) is the principal curcuminoid of turmeric, a perennial rhizomatous plant of the Zingiberaceae family native to tropical and subtropical regions. The three major chemical components of turmeric—curcumin, demethoxycurcumin, and bisdemethoxycurcumin—are collectively referred to as curcuminoids, with curcumin being the most abundant and biologically active constituent.
Curcumin has been extensively studied for its broad-spectrum pharmacological activities, including anti-inflammatory, antioxidant, anticancer, neuroprotective, and immunomodulatory effects. It modulates key signaling pathways such as NF-κB, NLRP3 inflammasome, and Nrf2, contributing to its diverse therapeutic potential. However, its clinical utility is severely limited by poor oral bioavailability. Liposomal encapsulation addresses this challenge by protecting curcumin from degradation and enhancing its delivery to target cells.
Curcumin presents significant formulation challenges. The compound is practically insoluble in water, degrades rapidly under alkaline conditions, and undergoes extensive first-pass metabolism in the intestine and liver. Following oral administration of conventional curcumin, the vast majority is metabolized by intestinal flora or excreted before absorption, with only a small fraction reaching systemic circulation. Native curcumin exhibits poor intestinal permeability, and its low solubility further limits absorption.
Liposomal encapsulation provides three critical advantages:
1. Solubility and Stability Enhancement — By encapsulating curcumin within a sunflower phospholipid bilayer, its solubility and stability are significantly improved. The encapsulation of liposomes forms an independent nanoparticle that can increase the solubility of curcumin in water while protecting it from external environmental factors including light, heat, and oxidation. The liposomal membrane shields curcumin from enzymatic degradation in the gastrointestinal tract, preserving its intact molecular structure until reaching target cells.
2. Enhanced Cellular Uptake — Liposomes fuse directly with intestinal cell membranes, facilitating efficient cellular delivery and bypassing passive diffusion limitations. In a human clinical trial, liposomal curcumin achieved a maximum plasma concentration of 423 ng/mL versus 34 ng/mL for free curcumin, confirming substantially improved systemic exposure.
3. Superior Bioavailability — A randomized, double-blind, clinical trial compared a novel double-layered nano-liposomal curcumin (BNT–C060) versus conventional free curcumin in healthy male volunteers. The liposomal formulation demonstrated 23.2-fold higher dose-normalized plasma AUC₀–ₜ (5.00 vs. 0.22 ng·h/mL/mg), 53-fold higher Cmax (1.06 vs. 0.02 ng/mL/mg), and 35.3-fold higher urinary exposure. Tmax was also significantly earlier (0.86 vs. 3.3 h), indicating faster absorption. A single oral dose of the liposomal formulation was generally well tolerated within the evaluated dose range, with no clinically significant safety signals observed.
| Field | Details |
|---|---|
| Product Name | Liposomal Curcumin 70% |
| CAS No. | 458-37-7 |
| Active Ingredient | Curcumin (Curcuminoid Complex) |
| Assay Method | RP-HPLC with C18 column; mobile phase acetonitrile and 20 mM potassium dihydrogen orthophosphate (pH 3.0) at 55:45 ratio; detection at 420 nm; LC-MS/MS for identity confirmation |
| Purity | ≥ 70% curcumin (HPLC); ≥ 95% assay available |
| Appearance / Color | Orange-yellow to yellow fine powder |
| Dosage Form | Liposomal powder, water-dispersible |
| Recommended Dosage | 200–1,000 mg per day; clinical studies have evaluated liposomal curcumin at 50 mg twice daily and doses up to 400 mg/m² IV |
| Application | Joint health, antioxidant support, anti-inflammatory support, metabolic function, neuroprotection, immune function, healthy aging |
| Extract Source | Curcuma longa L. rhizome extract (turmeric); sunflower phospholipid liposomal carrier |
| Molecular Formula | C₂₁H₂₀O₆ |
| Molecular Weight | 368.37 g/mol |
| Lead Time | In stock: 3–5 business days; Bulk/custom orders: 2–3 weeks |
| Shipping Method | International Express (FedEx / DHL / UPS); air and sea freight available; worldwide shipping including remote areas |
| Storage | Cool, dry place away from direct sunlight, heat, and moisture; keep container tightly sealed. Shelf life: 24 months when properly stored in unopened original packaging |
High Purity — Standardized to ≥70% curcumin by HPLC, ensuring consistent active content.
Liposomal Enhancement — Sunflower phospholipid bilayer encapsulation achieves encapsulation efficiency of approximately 86% with particle size of 100–120 nm and zeta potential of −31 to −55 mV.
Human Clinical Validation — Randomized, double-blind clinical trial demonstrated 23.2-fold higher plasma AUC₀–ₜ, 53-fold higher Cmax, and 35.3-fold higher urinary exposure compared to free curcumin.
Superior Plasma Concentration — Liposomal curcumin achieved Cmax of 423 ng/mL versus 34 ng/mL for free curcumin in human pharmacokinetic study.
Faster Absorption — Tmax of 0.86 h versus 3.3 h for free curcumin, indicating significantly faster onset of action.
Anti-Inflammatory Mechanisms — Curcumin inhibits NF-κB signaling, reduces mitochondrial ROS generation, and suppresses NLRP3 inflammasome activation.
Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.
Clean-Label Compatible — Non-GMO sunflower phospholipid carrier; no synthetic excipients.
Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.
| Application | Recommended Usage | Notes |
|---|---|---|
| Capsules / Tablets | 200–500 mg per serving | Take with meals to enhance absorption |
| Functional Beverages | 100–250 mg per 250 mL | Water-dispersible; suitable for RTD formats |
| Powdered Drink Mixes | 200–500 mg per sachet | Blend with piperine or phospholipids for synergistic absorption |
| Joint Health Formulas | 250–500 mg per serving | Randomized trial used 50 mg liposomal curcumin twice daily perioperatively |
| Anti-Inflammatory Formulas | 250–500 mg per serving | Often combined with boswellia, quercetin, or omega-3 fatty acids |
Clinical studies have evaluated liposomal curcumin across a range of doses. A randomized controlled trial in patients undergoing total laparoscopic hysterectomy used 50 mg oral liposomal curcumin twice daily, starting on preoperative day 1 and continuing for 2 postoperative days, demonstrating significantly lower postoperative 24-hour VAS scores (1.0 ± 0.4 vs 1.8 ± 1.1 for placebo; p = 0.007) and higher quality of recovery scores (112.4 ± 2.2 vs 105.6 ± 5.8; p < 0.001). A Phase I/II study evaluating intravenous liposomal curcumin in combination with standard radiation and temozolomide in patients with newly diagnosed high-grade gliomas used weekly doses of 300, 350, and 400 mg/m². For general antioxidant and anti-inflammatory support, 200–500 mg daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.
Stock Orders: 3–5 business days after payment confirmation.
Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.
Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.
Coverage: Worldwide shipping, including remote areas.
Curcumin Encyclopedia — Scientific Background
Curcumin (diferuloylmethane or curcumin I) is a polyphenolic compound and the principal curcuminoid of turmeric (Curcuma longa L.). It is a natural phenolic compound responsible for the yellow color of turmeric and belongs to the diarylheptanoid class of natural products. Curcumin is practically insoluble in water but soluble in organic solvents including ethanol, dimethyl sulfoxide, and acetone.
| Property | Value |
|---|---|
| CAS No. | 458-37-7 |
| Molecular Formula | C₂₁H₂₀O₆ |
| Molecular Weight | 368.37 g/mol |
| IUPAC Name | (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione |
| Appearance | Orange-yellow crystalline powder |
| Solubility | Practically insoluble in water; soluble in ethanol, DMSO, and acetone |
| Melting Point | 183°C |
Turmeric (Curcuma longa L.) is a perennial rhizomatous plant of the Zingiberaceae family, native to tropical and subtropical regions. The turmeric spice is produced from Curcuma longa rhizomes and represents the authentic crude source of curcumin. Dried C. longa rhizomes contain 3–15% of curcumin and its congeneric metabolites, collectively referred to as curcuminoids. The three major chemical components are curcumin (curcumin I), demethoxycurcumin (curcumin II), and bisdemethoxycurcumin (curcumin III).
Curcumin is a natural polyphenol derived from Curcuma longa and offers a promising approach to inhibit NLRP3-induced inflammation owing to its multi-targeted actions and excellent safety profile. The NLRP3 inflammasome is a key molecular complex that amplifies inflammatory cascades by maturing interleukin-1 beta (IL-1β) and interleukin-18 (IL-18) and inducing pyroptosis. It serves as a major driver and co-driver of numerous diseases associated with chronic inflammation, including rheumatoid arthritis, inflammatory bowel disease, neurodegenerative diseases, and atherosclerosis.
Preclinical models have demonstrated that curcumin inhibits nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, reduces mitochondrial reactive oxygen species (ROS) generation, and suppresses caspase-1 activation and apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) assembly, thereby inhibiting inflammasome activation. Curcumin has successfully prevented IL-1β-induced biological effects, tissue damage, and clinical manifestations in models of arthritis, colitis, and Alzheimer’s disease. The anti-inflammatory effect of curcumin on neurological disorders involves modulation of key signaling pathways (NF-κB, NLRP3 inflammasome, and Nrf2) and upregulation of anti-inflammatory cytokines (TGF-β and interleukin-10).
Curcumin activates the Nrf2/antioxidant response element (ARE) pathway, inducing the expression of endogenous antioxidant enzymes including heme oxygenase-1 (HO-1), catalase, and superoxide dismutase. It also directly scavenges free radicals and reactive oxygen species, protecting cellular components from oxidative damage.
Curcumin regulates multiple signaling pathways involved in cancer progression, including PI3K/AKT/mTOR, Wnt/β-catenin, and MAPK/ERK1. It enhances apoptosis and autophagy by activating CASP3, inhibits metastasis by reducing the secretion of MMP and VEGF, and downregulates mutant TP53 proteins, demonstrating selective toxicity targeting multiple cancer types. Various preclinical cell culture and animal studies suggest that curcuminoids have extensive biological activity as antioxidants, neuroprotective agents, antitumor agents, and anti-inflammatory agents.
Curcumin has demonstrated neuroprotective effects through modulation of neuroinflammatory pathways, reduction of oxidative stress, and inhibition of amyloid-beta aggregation. It suppresses neuroinflammation by modulating NF-κB and NLRP3 inflammasome signaling and upregulating anti-inflammatory cytokines.
Curcumin modulates lipid and glucose metabolism through activation of AMPK and inhibition of lipogenesis. It has been investigated for its effects on metabolic syndrome, insulin resistance, and non-alcoholic fatty liver disease.
Despite its broad pharmacological potential, curcumin presents significant formulation challenges. The compound is practically insoluble in water, has limited solubility in organic solvents, and is highly susceptible to degradation under alkaline conditions. Following oral administration, curcumin undergoes rapid metabolism in the intestine and liver, with extensive conjugation into glucuronides and sulfates. The poor oral bioavailability of curcumin has been attributed to its poor aqueous solubility, rapid metabolism, and poor intestinal permeability.
A pharmacokinetic study in healthy human volunteers comparing Liposomal Curcumin versus conventional free curcumin demonstrated the magnitude of the bioavailability challenge. Following a single oral dose of 400 mg curcumin-equivalent liposomal formulation versus 2,000 mg free curcumin, the liposomal formulation achieved 23.2-fold higher dose-normalized plasma AUC₀–ₜ (5.00 vs. 0.22 ng·h/mL/mg), 53-fold higher Cmax (1.06 vs. 0.02 ng/mL/mg), and 35.3-fold higher urinary exposure. Tmax was earlier (0.86 vs. 3.3 h). The liposomal formulation achieved substantially higher plasma concentrations (Cmax 423 ng/mL vs. 34 ng/mL free curcumin), suggesting improved systemic exposure with the nano-liposomal formulation.
Liposomal encapsulation of curcumin provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the curcumin molecule, forming a shield that protects it from environmental degradation and enzymatic metabolism. This delivery system:
Protects curcumin from oxidation and degradation under light, heat, and humidity
Enhances solubility and water dispersibility
Improves cellular uptake through membrane fusion
Significantly enhances oral bioavailability
Optimized liposomal curcumin formulations achieve encapsulation efficiency of approximately 86% with particle size of 100–120 nm and zeta potential of −31 to −55 mV. Quality evaluation criteria for B2B buyers include validated encapsulation efficiency (≥70% typical), particle size distribution (typically 100–200 nm), HPLC-verified assay (≥95% curcumin), and batch-specific Certificates of Analysis.
A prospective, randomized, double-blind, placebo-controlled pilot trial evaluated the effect of liposomal curcumin on early postoperative pain and quality of recovery in patients undergoing total laparoscopic hysterectomy. Forty patients were randomly divided into a liposomal curcumin group (n=20) and a placebo group (n=20). The study group received 50 mg oral liposomal curcumin twice daily, starting on preoperative day 1 and continuing for 2 postoperative days. Postoperative 24-hour VAS scores were significantly lower in the liposomal curcumin group compared to the placebo group (1.0 ± 0.4 vs 1.8 ± 1.1; p = 0.007). Total QoR-15 scores were significantly higher in the liposomal curcumin group (112.4 ± 2.2 vs 105.6 ± 5.8; p < 0.001), indicating improved functional quality of recovery. No side effects were observed.
A Phase I/II study evaluated liposomal curcumin in combination with standard radiation and temozolomide in patients with newly diagnosed high-grade gliomas. Liposomal curcumin was administered weekly at dose levels of 300, 350, and 400 mg/m². The combination was safe and well tolerated, with encouraging exploratory efficacy signals, and further evaluation in an expanded Phase II/III study is planned.
A single oral dose of the nano-liposomal curcumin formulation was generally well tolerated in healthy male volunteers within the evaluated dose range, with no clinically significant safety signals observed. In a Phase I/II study of liposomal curcumin in combination with standard chemoradiation for high-grade gliomas, the combination was safe and well tolerated. Curcumin has been demonstrated to be safe for use at a dose of 1,500 mg/day in a 12-month cardiometabolic study.
Curcumin is generally well tolerated. Clinical trial research demonstrates that curcumin levels of up to 1,000 mg per day are safe for consumption, with studies safely tolerating doses up to 1,500 mg/day in long-term studies and up to 400 mg/m² intravenously in cancer patients. In a Phase I/II study, liposomal curcumin combined with standard chemoradiation was safe and well tolerated. High doses may cause gastrointestinal discomfort in some individuals. Liposomal encapsulation helps reduce these side effects through sustained release and improved absorption. Curcumin is widely commercialized as a dietary supplement ingredient. In the United States, curcumin has FDA-GRAS reference documentation. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.
This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.
129$/KG
109$/KG
RELATED
RELATED
This website uses cookies to ensure you get the best experience on our website.
Español
Français
Deutsch
日本語
한국어
Phone
Comment
（0）